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ABSTRACT
Aims To estimate whether opioid substitution treatment (OST) with buprenorphine or methadone is associated with a
greater reduction in the risk of all-cause mortality (ACM) and opioid drug-related poisoning (DRP) mortality.
Design Cohort study with linkage between clinical records from Clinical Practice Research Datalink and mortality reg-
ister. Setting UK primary care. Participants A total of 11033 opioid-dependent patients who received OST from 1998
to 2014, followed-up for 30410 person-years.Measurements Exposure to methadone (17373, 61%) OST episodes or
buprenorphine (9173, 39%) OSTepisodes. ACMwas available for all patients; information on cause of death and DRPwas
available for 5935 patients (54%) followed-up for 16363 person-years. Poisson regression modelled mortality by treat-
ment period with an interaction between OST type and treatment period (ﬁrst 4 weeks on OST, rest of time off OST, ﬁrst
4 weeks off OST, rest of time out of OST censored at 12 months) to test whether ACM or DRP differed between methadone
and buprenorphine. Inverse probability weights were included to adjust for confounding and balance characteristics of pa-
tients prescribedmethadone or buprenorphine. Findings ACMand DRP rates were 1.93 and 0.53 per 100 person-years,
respectively. DRP was elevated during the ﬁrst 4 weeks of OST [incidence rate ratio (IRR) = 1.93 95% conﬁdence interval
(CI) = 0.97–3.82], the ﬁrst 4 weeks off OST (IRR = 8.15, 95% CI = 5.45–12.19) and the rest of time out of OST
(IRR = 2.13, 95% CI = 1.47–3.09) compared with mortality risk from 4 weeks to end of treatment. Patients on
buprenorphine compared with methadone had lower ACM rates in each treatment period. After adjustment, there was
evidence of a lower DRP risk for patients on buprenorphine comparedwithmethadone at treatment initiation (IRR=0.08,
95% CI = 0.01–0.48) and rest of time on treatment (IRR = 0.37, 95% CI = 0.17–0.79). Treatment duration (mean and
median) was shorter on buprenorphine thanmethadone (173 and 40 versus 363 and 111, respectively). Model estimates
suggest that there was a low probability that methadone or buprenorphine reduced the number of DRP in the population:
28 and 21%, respectively. Conclusions In UK general medical practice, opioid substitution treatment with buprenorphine
is associated with a lower risk of all-cause and drug-related poisoning mortality than methadone. In the population,
buprenorphine is unlikely to give greater overall protection because of the relatively shorter duration of treatment.
Keywords Buprenorphine, drug related deaths, methadone, mortality, opioids, opioid substitution treatment,
treatment cohort.
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INTRODUCTION
People with opioid dependence have more than 10 times
the risk of premature mortality than the general popula-
tion, and often cycle in and out of drug treatment before
achieving stable remission and cessation of opioid use
[1–6]. Methadone and buprenorphine are effective and
essential medicines for the management of opioid depen-
dence [7,8]. Opioid substitution treatment (OST) has posi-
tive beneﬁts across multiple outcomes on mortality risk,
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transmission of HIVand hepatitis C virus (HCV), HIV treat-
ment prognosis and drug-related crime [1,9–16]. OST is
highly cost-effective, whether delivered in the community
or prison [17–19]. Prolonged OST is associated with im-
proved survival [5]; however, recent studies highlight very
high mortality risk in the month after treatment cessation
[20–23]. There have also been reports of an elevated risk
of mortality during the ﬁrst month of OST [20,21,24,25].
Buprenorphine became available in the United
Kingdom in 1998 and OST has expanded more than ﬁve-
fold since 2000 [26]. However, trends in the overall num-
ber of drug and opioid-related deaths continue to rise,
with the highest number ever recorded at more than
1200 deaths in 2015/16 [27]. In the United States, more
than 60000 people died from an overdose in 2016: a four-
fold increase in the last 15 years [28]. While methadone is
a full mu-opioid agonist, buprenorphine is a partial mu-
opioid agonist, providing a ‘ceiling effect’ for respiratory de-
pression and potentially limiting the effect of additional
heroin use [29,30]. Qualitative studies in the United
States suggest that patient preference for buprenorphine
and methadone varies, and is inﬂuenced by peer attitudes,
prior treatment experience and clinic dispensing practices
[31–33]. Internationally, there is no consensus about
which medication to use. In the United Kingdom, metha-
done is recommended as the ﬁrst-line treatment if there
are no contraindications [8].
In a recent US randomized controlled trial, patients
with opioid dependence who received buprenorphine had
a shorter duration of treatment and were more likely to
drop out than those receivingmethadone [34]. This associ-
ation has been reported by systematic reviews [19,35]. A
recent Australian cohort study of OST patients reported
that the risk of death during the ﬁrst 4 weeks was lower
for buprenorphine compared to methadone—with no
marked differences in mortality risk thereafter [24]—but
with a shorter duration of treatment for patients on
buprenorphine compared to methadone [21,36,37].
In the present study we examine relative mortality risk
for patients with opioid dependence in primary care who
receive buprenorphine or methadone. Our hypothesis was
that buprenorphine is associated with a reduced mortality
risk during OST, especially during the ﬁrst 4 weeks of OST,
and fewer opioid drug-related poisoning (DRP) deaths in
the population.
METHODS
Study setting and databases
The study setting was general practitioner (GP) primary
care practices in the United Kingdom reporting to the Clin-
ical Practice Research Datalink (CPRD https://www.cprd.
com/home/) (ISAC CPRD Protocol 14_073R2). The CPRD
contains anonymized patient records from 674 GP
practices and more than 11 million patients (some 7% of
the UK population). CPRD is representative in terms of
socio-demographic characteristics and has good validity
and replicability in relation to chronic illness [38–40].
Linked cause-speciﬁc mortality data from the Ofﬁce for Na-
tional Statistics (ONS) are available on more than half the
records only for GP practices (395) in England [38].
Patient cohort and OST exposure
We constructed a UK cohort from an extract of CPRD for
49279 patients who received one or more prescriptions
of methadone or buprenorphine between 1 January
1998 and 31 July 2014 (Fig. 1). Treatment episodes were
periods of continuous prescription. If there was a gap of at
least 28 days between the expected completion of one pre-
scription and the start of the next, this was categorized as a
new treatment episode [20].
Using diagnostic and prescription formulation informa-
tion, we excluded 26324 patients who were prescribed
buprenorphine or methadone for pain relief, as well as
9950 patients who received doses below the minimum ex-
pected for OST (i.e. < 20 mg/day methadone or
< 4 mg/day buprenorphine). Patients outside the 15–64-
year age range were also dropped and all OST episodes
involving both methadone and buprenorphine within a
single OSTepisode to allow generation of propensity scores.
In total, 606 GP practices had at least one patient on OST
with information on all deaths. The ﬁnal risk set yielded
11033 patients followed-up for 30410 person-years over
26546 episodes and 512581 prescriptions, with an aver-
age duration of 14 days; 17373 (61%) OST episodes were
methadone and 9173 (39%) OST episodes were
buprenorphine.
Linkage to information on cause of death was available
for 5935 patients (54%) followed-up for 16363 person-
years, comprising 9550 (61%) OSTepisodes onmethadone
and 6050 (39%) on buprenorphine.
We estimated treatment duration from completed epi-
sodes and imputing for patients still in OST at the end of
follow-up based on averaging 100 predictions from the
log-normal distributions estimated by a parametric
survival analysis.
Outcome measures
All-cause mortality (ACM) was derived from dates of death
recorded within CPRD and DRP classiﬁed from the under-
lying cause of death (Supporting information, Table S1)
[27,41,42].
Statistical analyses
Each OST episode was modelled as four periods of expo-
sure [20,24,43]: weeks 1–4 on OST, rest of time on OST,
2 Matthew Hickman et al.
© 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
weeks 1–4 off OST and rest of time off OST censored at
12 months after each treatment episode. This censoring
avoided cumulative dilution of mortality risks by exclud-
ing periods where patients may have ceased opioid use
and minimized immortal time bias. Mortality incidence
rate ratios (IRRs) of ACM or DRP were estimated using
Poisson regression. We ﬁrst ﬁtted models with a random
effect of GP practice. However, with minimal evidence of
clustering [variance by practice = 0.2, 95% conﬁdence
interval (CI) = 0.1–0.5] we judged it appropriate to con-
duct the analysis without including clustering at practice
level. The main hypothesis was tested by ﬁtting an inter-
action between OST modality and treatment period. IRRs
are reported relative to methadone for each treatment
period.
Confounding
We ﬁrst adjusted for sex, age, calendar year, comorbidity
score and geographical region following earlier analyses
[20,21,44,45]. Comorbidity was calculated based upon
17 chronic illnesses and their associated weights, as de-
ﬁned by Khan et al. [46], and was incorporated as a time-
varying score (0, 1, 2 or more).
Several characteristics were also included that could in-
ﬂuence mortality risk: (a) benzodiazepine co-prescription;
Figure 1 Flow diagram of clinical practice research datalink extract and cohort risk set for analysis: patients prescribed methadone or buprenorphine
1998–July 2014 for opioid substitution treatment (OST). The above ﬁgure shows numbers of episodes, patients and deaths for the all-cause and drug-
related data sets. Identiﬁcation of prescriptions for pain relief were based upon prescription text, medication in the form of patches or episodes of
dihydrocodeine prior to starting OST. The follow-up period varied by patient and reﬂected a combination of the study period (January 1998–July
2014), the patient registration period with the primary care practice, the Clinical Practice Research Datalink (CPRD) usable data date and 1 year after
the last treatment ended. The exclusion of periods greater than 1 year after the cessation of treatment for each episode (immortal time bias) affected
the person-years at risk, but not the number of deaths [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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(b) gabapentoid co-prescription; (c) number of OST patients
per GP practice; (d) number of GPs prescribing per practice;
and (e) history recorded of self-harm, overdose poisoning,
alcohol problems, imprisonment or homelessness. We gen-
erated propensity scores (see Supporting information, Ap-
pendix S1) on the probability of being prescribed
buprenorphine and incorporated these as inverse probabil-
ity weight (IPW) into regression models to balance the co-
variates between the two OST medication groups and
improve model stability [47]. An extended analysis using
matched propensity scores could only be undertaken for
ACM [47] (Supporting information, Appendix S1).
We observed a difference in mortality risk by age and
comorbidity for patients prescribed methadone or
buprenorphine and so included an interaction between
OSTmodality and age and comorbidity in the ﬁnal adjusted
models.
Sensitivity analyses
We undertook a series of sensitivity analyses, as follows.
1 In the United Kingdom, OST is delivered in the commu-
nity by primary care and community drug agencies of-
ten managed by third-sector providers. We tested that
treatment duration on methadone and buprenorphine
was similar for patients treated in primary care or
through third-sector service providers.
2 We testedwhether the differences in the patternmortal-
ity risk by period for patients on buprenorphine and
methadone persisted for patients and OSTepisodeswith-
out comorbidity.
3 We compared Poisson regression with negative bino-
mial regression to account for overdispersion in the
results.
4 We tested whether the ﬁndings changed after adjust-
ment for evidence of planned discharge (tapering OST
prior to discharge/cessation).
Other sensitivity analyses not reported below (Tables
available on request) include: (5) addressing immortal time
bias by dropping all episodes that began before patients
were transferred into CPRD or follow-up began or includ-
ing only the last treatment episode (no change in results)
[48]; and testing that the direction and magnitude of IRR
between buprenorphine and methadone were robust to
changing the minimum gap between episodes (e.g. moving
from fewer than 28 days to 7 days) (they were).
Effect of OST on DRP mortality in the population
(Supporting information, Appendix S2)
We estimated the probability that OST reduces DRP in the
population by calculating weighted mortality risk ratios
(wMRR) of DRP deaths. wMRR compare the observed
mortality risk in patients undergoing OST to assumed
mortality risk of opioid-dependent patients who do not en-
ter OST (accounting for ﬂuctuating mortality risk in differ-
ent periods on and off OST, and for variation in the
duration of current treatment). We also estimate the min-
imum median duration of methadone and buprenorphine
required to reduce DRP deaths in the population
(Supporting information, Appendix S2).
RESULTS
Patient and OST characteristics
Table 1 shows patient, OST episode and practice charac-
teristics. The proportion of buprenorphine episodes in-
creased from < 20% in 1998–2000 to 41% in 2010–
14. Mean (and median) duration of episodes was 363
(111) days and 173 [40] days for methadone and
buprenorphine, respectively. The mean [standard devia-
tion (SD)] dose for methadone was 65.3 mg/day (66.1)
and 7.5 mg/day (9.2) for buprenorphine; 43% of metha-
done and 21% of buprenorphine episodes met the recom-
mended therapeutic daily dose of ≥ 60 mg and ≥ 12 mg,
respectively [49].
Approximately 15% of all OST episodes and fewer than
10% of OSTepisodes lasting less than 2months showed ev-
idence of a tapering dose towards a planned discharge from
treatment. The mean number of OST episodes was 2.4.
Sixty per cent of patients had OSTepisodes with only meth-
adone, and 10% had at least one buprenorphine and one
methadone OST episode.
Mortality
There were 587 deaths during OSTor within 12months of
treatment cessation, giving an overall mortality rate of
1.93 deaths per 100 person-years. There were 87 DRPs,
giving an overall mortality rate of 0.53 deaths per 100
person-years. Table 2 shows the ACM rates, DRP rates
and unadjusted and adjusted IRRs by OST period and
modality.
Confounders and propensity scores
Buprenorphine prescription varied by region, calendar
period and practice size (Supporting information, Table
S2). Women, older and more comorbid patients and
patients co-prescribed gabapentoids were more likely to
be prescribed buprenorphine. Patients co-prescribed benzo-
diazepines and with a reported history of self-harm, over-
dose, alcohol problems, imprisonment and homelessness
were more likely to be prescribed methadone. Supporting
information, Table S2 shows that IPW provided a better
balance of covariates (towards 50 : 50) between patients
treated with buprenorphine or methadone.
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Table 1 Patient, opioid substitution treatment (OST) episode and practice characteristics.
Characteristic Category
No. (%)
Total Linked to DRP recordsc
Patients 11 033 (100.00) 5935 (100.00)
Gender Female 3570 (32.36) 1851 (31.19)
Age (years) (on entry) < 30 3468 (31.43) 1876 (31.61)
30–39 4425 (40.11) 2409 (40.59)
40–49 2020 (18.31) 1124 (18.94)
50+ 1120 (10.15) 526 (8.86)
Comorbidity score 0 7619 (69.06) 4178 (70.40)
(at exit from study) 1 2454 (22.24) 1409 (23.74)
2+ 960 (8.70) 348 (5.86)
OST medication Methadone 7633 (69.18) 3745 (63.10)
Buprenorphine 2619 (23.74) 1656 (27.90)
Both 781 (7.08) 534 (9.00)
Benzodiazepines Yes 4853 (43.99) 2430 (40.94)
Gabapentin/pregabalin Yes 901 (8.17) 426 (7.18)
Self-harm history Yes 209 (1.89) 87 (1.47)
Overdose history Yes 2449 (22.20) 1381 (23.27)
Alcohol problems Yes 2048 (18.56) 1068 (17.99)
Prison history Yes 663 (6.01) 335 (5.64)
Homeless history Yes 260 (2.36) 131 (2.21)
OST episodes 26 546 (100.00) 15 600 (100.00)
Methadone All episodes 17 373 (65.44) 9550 (61.22)
By duration Up to 1 month 4915 (28.29) 2923 (30.61)
1–< 3 months 3157 (18.17) 1828 (19.14)
3–< 6 months 2443 (14.06) 1381 (14.46)
6–< 12 months 2298 (13.23) 1213 (12.70)
12 months or longer 4560 (26.25) 2205 (23.09)
Buprenorphine All episodes 9173 (34.56) 6050 (38.78)
By duration Up to 1 month 4128 (45.00) 2704 (44.69)
1–< 3 months 2007 (21.88) 1329 (21.97)
3–< 6 months 1109 (12.09) 755 (12.48)
6–< 12 months 826 (9.00) 556 (9.19)
12 months or longer 1103 (12.02) 706 (11.67)
By year of initiation 1998–2000 2726 (83.20) 1434 (84.73)
(% methadone) 2000–2004 8730 (69.53) 4750 (64.99)
2005–2009 9157 (60.43) 5583 (56.67)
2010–2014 5933 (59.01) 3833 (54.37)
Completed/uncensored 23 685 (89.22) 14 234 (91.24)
Planned dischargea < 2 months 945 (7.94) 588 (7.93)
(by duration) 2+ months 2596 (22.02) 1472 (21.60)
Methadone All completed 15 117 (63.83) 8550 (89.53)
Maximum dose ≥ 60 mg per day 6539 (43.26) 3210 (37.54)
Buprenorphine All completed 8568 (36.17) 5684 (93.95)
Maximum dose ≥ 12 mg per day 1833 (21.39) 1271 (22.36)
GP practices 606 (100.00) 352 (100.00)
OST patientsb 1–2 285 (47.03) 162 (46.02)
3–9 227 (37.46) 132 (37.50)
10+ 94 (15.51) 58 (16.48)
Prescribing GPsb 1–4 135 (22.28) 67 (19.03)
5–9 261 (43.07) 141 (40.06)
10+ 210 (34.65) 144 (40.91)
Region North East 11 (1.82) 9 (2.56)
North West 74 (12.21) 58 (16.48)
Yorkshire/Humber 29 (4.79) 17 (4.83)
(Continues)
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Mortality by treatment period
Table 2 shows that ACM and DRP vary considerably by
treatment period. At the lowest risk period from 4 weeks
on OST until treatment cessation the ACM and DRP mor-
tality rates were 0.98 and 0.29 per 100 person-years, re-
spectively. Compared to being on OST during that period
(our referent) the ACM risk was more than three times
(95% CI = 2.31–4.36) higher during the ﬁrst 4 weeks of
treatment, nearly 10 times (95% CI = 7.87–12.01) higher
during the ﬁrst 4 weeks after treatment ceased and more
than two times higher (95% CI = 1.82–2.73) in the rest
of the period out of treatment. Adjustment for sex, age,
year, comorbidity, region and OST modality or using IPW
did not alter these ﬁndings.
The IRR for DRP mortality risk was 3.03 (95%
CI = 1.37–6.66), 5.85 (95% CI = 3.22–10.63) and
2.20 (95% CI = 1.32–3.64) for the ﬁrst 4 weeks on
OST, the ﬁrst 4 weeks off OST and the rest of time off
treatment, respectively, compared to being on OST from
4 weeks to end of treatment. After adjustment using
IPW and other interactions (between OST modality and
age and comorbidity) the DRP mortality risk in the ﬁrst
4 weeks on OST reduced slightly (IRR = 1.93, 95%
CI = 0.97–3.82) and the mortality risk during the ﬁrst
4 weeks after treatment ceased increased slightly
(IRR = 8.15, 95% CI = 5.45–12.19) compared to the
rest of time on OST.
Buprenorphine compared to methadone
Patients on buprenorphine compared to methadone had a
lower all-cause mortality (ACM) rate in each treatment
period. Adjusting for sex, age, year, comorbidity and region
or using IPW or matching on propensity score tended
to strengthen the difference in ACM risk between
buprenorphine and methadone (Fig. 2).
DRP during the ﬁrst 4 weeks of OST was 1.24 per
100 person-years for patients on methadone compared
to 0.30 per 100 person-years for patients on
buprenorphine (Table 2). After adjustment (Fig. 2), in-
corporating IPW and interactions between OST modality
and age and comorbidity, evidence strengthened for a
difference in DRP for patients on buprenorphine com-
pared to methadone. Patients on buprenorphine had a
lower risk of DRP during the ﬁrst 4 weeks of treatment
(IRR = 0.08, 95% CI = 0.01–0.48), as well as the rest
of time on OST (IRR = 0.37, 95% CI = 0.17–0.79) com-
pared to patients on methadone. There was no evidence
for a difference in mortality risk for patients on
buprenorphine compared to methadone during the ﬁrst
4 weeks after treatment ceased, but a larger difference
in the period after the ﬁrst 4 weeks post-treatment to
12 months after termination of OST (IRR = 0.23, 95%
CI = 0.12–0.48).
Age and comorbidity
Table 3 shows evidence for interactions between age and
comorbidity with OST modality. ACM, but not DRP,
increased with age. For both ACM and DRP the risk of mor-
tality was lower in older patients prescribed buprenorphine
compared to patients prescribed methadone.
Comorbidity was associated with both ACM and DRP
and the risk of ACM and DRP was substantially lower for
comorbid patients prescribed buprenorphine compared to
methadone. The mortality risk was considerably higher
(15.9 per 100 person-years) for people with two or more
comorbidities, and 90% of the deaths in this group
Table 1. (Continued)
Characteristic Category
No. (%)
Total Linked to DRP recordsc
East Midlands 23 (3.80) 12 (3.41)
West Midlands 49 (8.09) 37 (10.51)
East 50 (8.25) 37 (10.51)
South West 56 (9.24) 46 (13.07)
South Central 48 (7.92) 35 (9.94)
London 73 (12.05) 56 (15.91)
South East 57 (9.41) 45 (12.78)
Northern Ireland 19 (3.14)
Scotland 71 (11.72)
Wales 46 (7.59)
aEvidence of a decrease in dose over last 28 days of OST—shown separately for episodes with < 2 months (11 897 total and 7418 linked episodes) and 2+
months duration (11 788 total and 6816 linked episodes). bAverage for each practice derived from5802 practice years. cLinked to Ofﬁce for National Statistics
(ONS) mortality register for information on drug-related poisonings (DRP). GP = general practitioner.
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occurred in people who were currently or last treated on
methadone.
Sensitivity analysis
Treatment duration for patients on buprenorphine and
methadone is highly skewed (as shown in Table 1, Fig. 4
and Supporting information, Table S3). We found
similar distributions in patients treated in primary care
(our observed CPRD data set) and a leading third-sector
provider of community drug treatment (Supporting infor-
mation, Table S3).
Supporting information, Table S4 showsmultiple sensi-
tivity analyses. These showed that the differential patterns
in mortality rates by the period on and off OST and
between patients receiving methadone or buprenorphine
remain for patients without comorbidity (i.e. when comor-
bid patients and episodes are excluded; see mortality rates
in model B). There are also similar mortality rates if mixed
OST episodes involving buprenorphine and methadone are
included (model C). The ﬁnal adjusted model shown in
Table 2 (model A) is robust to additional adjustment for
planned discharge (evidence of tapering dose prior to
cessation, model D) and alternative regression models
(negative binomial) that allow for overdispersion in the
outcome (model E).
Expected impact of OSTon DRP compared to no treatment
Figure 3 shows that there is insufﬁcient evidence that OST
reduces the number of DRP deaths in the population for
patients on methadone or buprenorphine: weighted mor-
tality rate ratio (wMRR) 1.55 (95% CI = 0.54–3.80) and
1.79 (95% CI = 0.48–5.24), respectively (see Supporting
information, Appendix S2). We estimated the probability
that methadone or buprenorphine reduces drug-related
deaths in the population to be 28 and 21%, respectively.
Modelling the impact of inducing all OST patients on
buprenorphine then switching either 50 or 100% patients
to methadone (given observed duration of treatment) im-
proves the probability of beneﬁt slightly, but it remains
lower than 50%.
Figure 2 Comparison of adjusted incidence rate ratios (IRR)
comparing mortality risk for patients on buprenorphine or
methadone by period on and off treatment with and without
propensity score weights and matching. The ﬁgure shows the
risk of mortality for buprenorphine relative to methadone for
the four treatment periods by all-cause a or drug related mortal-
ity b and by adjusted, propensity score based weighted analyses
(IPW), propensity score-matched analyses and IPW analyses
with additional adjustment for interactions of opioid substitution
treatment (OST) with age or comorbidity. Incidence rate ratios
are shown on a log scale with 95% conﬁdence intervals. Results
for matched episodes in drug-related mortality analyses are not
shown due to the small number of deaths [Colour ﬁgure can be
viewed at wileyonlinelibrary.com]
8 Matthew Hickman et al.
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Figure 4 shows that to reduce DRP by 25% by increas-
ing OST duration alone would require a minimummedian
duration of 202 days for buprenorphine and 387 days for
methadone: at 50% probability of success.
DISCUSSION
Main ﬁndings
We ﬁnd consistent evidence that buprenorphine is associ-
ated with lower ACM and DRP mortality compared to
methadone during the ﬁrst 4 weeks and during the re-
maining time in treatment. We raise the hypothesis that
buprenorphine has a greater effect on reducing mortality
risk compared to methadone for older and more comorbid
patients. However, in UK primary care the majority of pa-
tients receive comparatively short durations of treatment.
Patients prescribed buprenorphine had a substantially
lower average treatment duration than patients prescribed
methadone. The combination of short average treatment
durations and high mortality risk in the period after
Figure 3 Estimated weighted mortality risk ratios (wMRR) and corresponding probability of beneﬁt. A weighted mortality risk ratio (wMRR) com-
pares drug-related poisoning mortality risk for patients on opioid substitution treatment (OST) (based on the observed mortality risks and duration of
treatment shown in Table 1) and a hypothetical population of people who did not enter OST. A wMRR of 1 suggests that there is no difference in the
number of drug-related poisonings in the population for people on OST (with wMRR < 1 and > 1 suggesting survival improved or worsened and
lower or higher number of deaths in the population, respectively) compared to people not receiving OST. The wMRR also models the impact of
inducing all patients on buprenorphine then switching either 50 or 100% patients to methadone (given observed duration of treatment)
Figure 4 Length of treatment for patients on methadone or buprenorphine for opioid substitution treatment (OST) in primary care and estimated
minimum duration to achieve positive beneﬁt or a 25% reduction in drug-related poisonings (DRP). The ﬁgures show the distribution of OST duration
and estimated minimum treatment duration required to have a 50 or 80% chance of achieving a positive beneﬁt and a 25% reduction in DRP deaths
compared to not being on OST. Probability that OST patients beneﬁt (equivalent to wMRR< 1), or have a reduced risk of DRP by 25% (equivalent
to wMRR< 0.75), is determined by the proportion of samples that have weighted MRR below the corresponding threshold (see Supporting infor-
mation, Appendix S2)
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treatment cessation suggests that in the United Kingdom
neither buprenorphine or methadone are reducing the
number of DRPs in the population.
Strengths and limitations
Observational cohorts present the best evidence, as trials
are too underpowered to investigate differences in mortal-
ity risk in patients on OST [11,43,50]. Nonetheless, we ac-
knowledge several limitations. First, there were differences
in the distribution of confounders between patients pre-
scribed buprenorphine or methadone. However, using pro-
pensity scores to adjust for this uneven distribution of
confounders strengthened the intervention effect of
buprenorphine compared to methadone for reducing
DRP during the ﬁrst 4 weeks of treatment and during the
other time-periods. The presence of differences in mortality
risks between patients prescribed methadone or
buprenorphine more than 4 weeks after treatment ceased
implies residual confounding. It has been argued that pa-
tients prescribed buprenorphine may be less severely
addicted and more likely to recover than those prescribed
methadone. However, in our study we found that older
and more comorbid patients were more likely to be pre-
scribed buprenorphine, and by the last calendar period
(2010–14) more than 40% of patients were prescribed
buprenorphine. We included information on self-harm,
previous overdose, alcohol use, prison history and home-
lessness in propensity-score adjustments, and crucially we
found no evidence of a difference in DRP during the ﬁrst
4 weeks after leaving treatment, when one would expect
any difference in relapse rates between patients on metha-
done and buprenorphine to have the greatest inﬂuence.
Unfortunately, it is a common problem that large drug
treatment cohorts lack reﬁned measures on addiction se-
verity and patient or clinical perceptions and preferences
on OST modality [22,24,43].
Secondly, our efforts to exclude patients prescribed
buprenorphine or methadone for pain relief (based on the
type of formulation, clinical diagnoses/indications and
minimum dose) may not have been entirely successful.
However, if there was misclassiﬁcation of OST episodes we
believe it was more likely to affect patients on
buprenorphine than methadone, as the former is used
more often for other indications than opioid dependence.
However, the mortality rates and patterns in DRP in and
out of treatment are also consistent with other cohorts,
and the same differential patterns of overdose by period
were seen in our data set after excluding comorbid treat-
ment episodes.
Thirdly, data on DRP were only available on half the
cohort, which did not add bias, because the reasons
(only available from GPs in England) were unrelated to
future mortality risk but reduced power. Fourthly, we
did not pre-specify testing the interaction between age
and comorbidity and OST type, and need to be cautious
on the interpretation both until replicated in other epide-
miological studies and tested in pharmacological and
clinical studies. Fifthly, there is no information on the
reason for treatment cessation, so we assumed that pa-
tients dropped out of treatment if there was no tapering
in the prescription dose during the last month of treat-
ment. We found no evidence that the shorter duration
for patients on buprenorphine was due to planned dis-
charge. Sixthly, our estimates of the minimum duration
required to achieve beneﬁt do not take account of any
other interventions that could reduce mortality risk. Fi-
nally, we are unable to compare whether patients seen
in UK primary care are more or less comorbid than pa-
tients in other community drug services.
Other evidence and implications
A recent systematic review concluded that OST reduces
mortality rates but could not make any direct or deﬁni-
tive conclusions when comparing methadone and
buprenorphine [43]. The review reported greater reduc-
tions in mortality risk between in and out of OST for pa-
tients prescribed methadone but lower overall mortality
rates in both periods for patients prescribed
buprenorphine.
We observed an ageing and increasingly comorbid pop-
ulation of opioid-dependent patients with comparatively
high rates of ACM, although consistent with other cohorts
and the increase in drug-related deaths in the UK popula-
tion [43,51]. Forensic data also suggest substantial comor-
bidity in people dying of an opioid overdose, and it has been
hypothesized that systemic illnessesmaycompromise phys-
iological and pharmacological responses to opioid action
on respiratory depression and opioid metabolism, thereby
increasing overdose risk [52,53]. A study in Scotland sug-
gested that mortality risk increased with age inmethadone
patients [54], although neither study can test the mecha-
nism of any increased risk.
Our ﬁndings are consistent with evidence from New
South Wales (NSW), Australia that showed a substantially
reduced risk of DRP in the ﬁrst 4 weeks of treatment for
patients on buprenorphine compared to methadone, the
scale of which is unlikely to be reversed through introduc-
ing additional unmeasured confounders [24]. However, the
NSW data did not observe the larger differences for
all-cause mortality and was unable to adjust for con-
founders which, in our study, tended to strengthen
differential effects [21].
Our data also align with trial and other observational
data suggesting that patients are less likely to be retained
on buprenorphine treatment compared to methadone
(i.e. that treatment duration is shorter) [19,34,37]. Long-
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term follow-up of trial participants reported no differences
in drug outcomes for patients randomized to
buprenorphine or methadone, but was underpowered to
detect differences in mortality [55].
Previously we highlighted that treatment duration
could be critical to preventing drug-related deaths in the
population [20]. The majority of drug-related deaths are
among individuals not in treatment [22,56]. Restricting
access to OST is associated with high rates of mortality
among opioid-dependent people who have been discharged
or denied treatment [57]. Open access to OST is a feature of
the ‘British System’ of drug treatment and a response to
HIV/AIDS epidemic in the early 1990s [58]. Coverage
and duration of OST is also critical to the prevention of
HIVand HCV in opioid-dependent people who inject drugs
[59,60]. However, our new analyses show that OST dura-
tion seems to follow an exponential decay, with the major-
ity of patients having comparatively short treatments and
not receiving maintenance therapy as intended, with
prolonged duration of treatment and planned tapered dis-
charge. Nosyk et al. has also shown in British Columbia
that the majority of patients do not discharge successfully
frommaintenance therapy [61], but a recent study inmul-
tiple sites suggests that the preponderance of shorter treat-
ments may be greater in the United Kingdom than
elsewhere [62]. For example, a study in Germany found
almost two-thirds of patients retained on OST at 1 year
[63,64].
At a population level our ﬁndings generate conﬂicting
pictures. Mortality risk is reduced during treatment, as
shown in reviews that compare mortality rates in and
out of OST [43], but our model estimates suggest that the
overall treatment duration, at least in UK primary care, is
too short to have a population beneﬁt. Moreover, the reduc-
tion in risk at treatment cessation for patients on
buprenorphine may be outweighed by less overall protec-
tion as a result of the short and skewed distribution in du-
ration of treatment. Our models also suggest that in the
United Kingdom a potential ‘quick ﬁx’, as suggested in ear-
lier reports, of inducing all OST patients on buprenorphine
and then switching patients to methadone, is unlikely to
lead to a substantial reduction in drug-related poisonings
in the population unless overall duration of treatment is ex-
tended [24]. Other large-scale epidemiological studies are
needed in order to strengthen the evidence and replicate
and test our ﬁndings, but interventions to improve OST re-
tention also are needed. Rather than compare OST modal-
ities against each other we need large trials in the United
Kingdom and elsewhere that can test how best to stratify,
combine and optimize OST alongside other behaviour
change interventions [65], both to reduce mortality risk
at induction and retain people in treatment long enough
to reduce the number of drug-related deaths in the
population.
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